Back to Journals » Clinical Ophthalmology » Volume 5

The use of mitomycin C with autologous limbal-conjunctival autograft transplantation for management of recurrent pterygium

Authors Fakhry M

Published 26 January 2011 Volume 2011:5 Pages 123—127

DOI https://doi.org/10.2147/OPTH.S16474

Review by Single anonymous peer review

Peer reviewer comments 5



Mohamed A Fakhry
Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt

Purpose: The purpose of this study is to evaluate and compare recurrence rates upon using mitomycin C (MMC) with limbal-conjunctival autograft for treating recurrent pterygia.
Methodology: An interventional, prospective, comparative clinical study was performed in 30 eyes (26 patients) with recurrent pterygia, allocated into two groups: Group A (19 eyes) operated by pterygium excision and limbal-conjunctival autograft transplantation (L-CAT) without MMC and Group B (20 eyes) operated with injection of 0.1 mL of MMC 0.15 mg/mL 1 month before L-CAT surgery. Exclusion criteria included patients with symblepharon, cicatricial conjunctival diseases, limbal stem cell deficiency, and other intraocular diseases.
Results: A total of four cases of recurrences for Group A (P = 0.012) and one case of recurrence for Group B (P < 0.001) were recorded.
Conclusions: Preoperative injection of MMC in low dose and concentration improves the results of L-CAT in recurrent pterygium.

Keywords: recurrent pterygium, limbal autograft, conjunctival autograft, mitomycin C

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.